Wu Juan, Zou Yang, Luo Yong, Guo Jiu-Bai, Liu Fa-Ying, Zhou Jiang-Yan, Zhang Zi-Yu, Wan Lei, Huang Ou-Ping
The College of Medicine, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Key Laboratory of Women's Reproductive Health of Jiangxi, Jiangxi Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi 330006, P.R. China.
Oncol Lett. 2017 Jul;14(1):47-54. doi: 10.3892/ol.2017.6120. Epub 2017 May 4.
Uterine leiomyomas (ULs) are the most common gynecological benign tumors originating from the myometrium. Prevalent mutations in the mediator complex subunit 12 (MED12) gene have been identified in ULs, and functional evidence has revealed that these mutations may promote the development of ULs. However, whether MED12 mutations are associated with certain clinical characteristics in ULs remains largely unknown. In the present study, the potential mutations of MED12 and its paralogous gene, mediator complex subunit 12-like (MED12L), were screened in 362 UL tumors from Han Chinese patients. A total of 158 out of 362 UL tumors (43.6%) were identified as harboring MED12 somatic mutations, and the majority of these mutations were restricted to the 44th residue. MED12 mutations were also observed in 2 out of 145 (1.4%) adjacent control myometrium. Furthermore, the mutation spectrum of MED12 in the concurrent leiomyomas was noticeably different. Correlation analysis of MED12 mutations with the available clinical features indicated that patients with mutated MED12 tended to have smaller cervical diameters. By contrast, no MED12L mutation was identified in the present samples. In summary, the present study demonstrated the presence of prevalent MED12 somatic mutations in UL samples, and the MED12 mutation was associated with smaller cervical diameters. The low mutation frequency of MED12 in adjacent control myometrium indicated that MED12 mutation may be an early event in the pathogenesis of ULs. Furthermore, MED12 mutation status in concurrent tumors from multiple leiomyomas supported several prior observations that the majority of these tumors arose independently.
子宫平滑肌瘤(ULs)是最常见的源自子宫肌层的妇科良性肿瘤。已在子宫平滑肌瘤中鉴定出中介体复合物亚基12(MED12)基因的普遍突变,并且功能证据表明这些突变可能促进子宫平滑肌瘤的发展。然而,MED12突变是否与子宫平滑肌瘤的某些临床特征相关在很大程度上仍不清楚。在本研究中,对362例汉族子宫平滑肌瘤患者的肿瘤进行了MED12及其旁系同源基因中介体复合物亚基12样(MED12L)的潜在突变筛查。362例子宫平滑肌瘤肿瘤中有158例(43.6%)被鉴定为携带MED12体细胞突变,并且这些突变大多数局限于第44位残基。在145例相邻对照子宫肌层中的2例(1.4%)中也观察到MED12突变。此外,同时存在的平滑肌瘤中MED12的突变谱明显不同。MED12突变与现有临床特征的相关性分析表明,MED12突变的患者宫颈直径往往较小。相比之下,在本样本中未鉴定出MED12L突变。总之,本研究证明子宫平滑肌瘤样本中存在普遍的MED12体细胞突变,并且MED12突变与较小的宫颈直径相关。相邻对照子宫肌层中MED12的低突变频率表明MED12突变可能是子宫平滑肌瘤发病机制中的早期事件。此外,多个平滑肌瘤同时发生的肿瘤中MED12突变状态支持了先前的一些观察结果,即这些肿瘤大多数是独立发生的。